/BMY
Bristol-Myers Squibb Company
BMY • NYSEBMY • NYSE • Healthcare
$60.29-0.74%-0.45
$60.29-0.74%(-0.45)Healthcare
GoAI Score
Sign in to unlock
Valuation
50Fair Value
Sentiment
53Neutral
Risk
100Low Risk
Momentum
86Positive
Institutional-Grade Intelligence
🏆PRO
Actionable Intelligence
AI-driven stance, execution logic & risk thresholds
Catalyst Roadmap
Event timeline with expected impact & market context
Deep Insights
Fact-checked analysis & score logic breakdown
Financial Statements
Margin Trends
Gross
67.6%▲10.9pp
Revenue after COGS
Operating
26.3%▲6.3pp
After operating expenses
Net
14.6%▲33.2pp
Bottom-line profitability
Gross Margin
Operating Margin
Net Margin
Valuation Snapshot
P/E Ratio
15.6
Price vs earnings
EV/EBITDA
10.1
Enterprise value
FCF Yield
11.7%
Cash generation
Earnings Yield
6.4%
Inverse of P/E
Capital Efficiency
20
GoAI Quality ScoreStrong
ROEReturn on Equity
38.2%Strong
ROAReturn on Assets
7.8%Strong
ROICReturn on Invested Capital
13.9%Strong
Financial Health
Current RatioAdequate
1.26
Short-term solvency (>1.5)
Net Debt / EBITDAManageable
2.54x
Debt repayment capacity (<3x)
Income QualityStrong
2.01
Cash backs earnings (>1)
Revenue & Profitability
Revenue
Net Income
Net Loss
Income Statement
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $48.19B | $48.30B | $45.01B | $46.16B | $46.38B |
| Gross Profit | $32.60B | $27.43B | $25.36B | $26.49B | $26.76B |
| Gross Margin | 67.6% | 56.8% | 56.3% | 57.4% | 57.7% |
| Operating Income | $12.70B | $9.66B | $8.47B | $9.27B | $9.54B |
| Net Income | $7.05B | -$8.95B | $8.03B | $6.33B | $6.99B |
| Net Margin | 14.6% | -18.5% | 17.8% | 13.7% | 15.1% |
| EPS | $3.46 | -$4.41 | $3.88 | $2.97 | $3.15 |
Average Price Target
$62.73▲ 4.0% Upside
Past 12 Months
12 Month Forecast
Based on 50 Wall Street analysts offering 12 month price targets for Bristol-Myers Squibb Company, the average price target is $62.73, with a high forecast of $75.00 and a low forecast of $40.00. The average price target represents a 4.0% increase from the current price of $60.29.
Highest
$75.00
Average
$62.73
Lowest
$40.00
Rating Distribution
Strong Buy
0
0%
Buy
19
46%
Hold
20
49%
Sell
2
5%
Strong Sell
0
0%
Recent Analyst Ratings
FirmActionRatingDate
Piper Sandler● Maintain
Overweight
2026-02-23Wells Fargo● Maintain
Equal Weight
2026-02-06Guggenheim● Maintain
Buy
2026-02-06Citigroup● Maintain
Neutral
2026-02-06Piper Sandler● Maintain
Overweight
2026-01-28Citigroup● Maintain
Neutral
2026-01-27Leerink Partners● Maintain
Outperform
2026-01-13Scotiabank● Maintain
Sector Perform
2026-01-09Citigroup● Maintain
Neutral
2026-01-07UBS▲ Upgrade
Neutral→Buy
2026-01-07Earnings History & Surprises
BEAT RATE
88%
Last 17 quarters
AVG SURPRISE
+9.9%
EPS vs Estimate
BEATS / MISSES
15/1
1 met exactly
LATEST EPS
$1.26
Q1 '26
QUARTERLY EPS TREND
Estimated
Beat
Miss
QUARTERLY DETAIL
Q1 '26
+2.4%
$1.26 vs $1.23
Q4 '25
+7.2%
$1.63 vs $1.52
Q3 '25
+33.9%
$1.46 vs $1.09
Q2 '25
+20.8%
$1.80 vs $1.49
Q1 '25
+13.6%
$1.67 vs $1.47
Q4 '24
+20.8%
$1.80 vs $1.49
Q3 '24
+27.8%
$2.07 vs $1.62
Q2 '24
+0.2%
$-4.40 vs $-4.41
Q1 '24
+11.8%
$1.70 vs $1.52
Q4 '23
+13.6%
$2.00 vs $1.76
Q3 '23
-12.1%
$1.75 vs $1.99
Q2 '23
+3.5%
$2.05 vs $1.98
No investor questions available.
Latest News
No news available